Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Levulinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levulinic Acid SCHEMBL377115 | 1.00 | ALDH1A1 (0.59) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL116039 | 0.97 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL30439842 | 0.94 | ALDH1A1 (0.59) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL8418932 | 0.94 | ALDH1A1 (0.59) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL8418934 | 0.94 | ALDH1A1 (0.59) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL28938456 | 0.94 | ALDH1A1 (0.59) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL25222492 | 0.91 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL21815796 | 0.91 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL10791493 | 0.91 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL21815652 | 0.91 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447285-B | A kind of crystal formation of calcium levulinate monohydrate | 广州白云山天心制药股份有限公司 | 2016-09-21 | — | — | CN | claimed |
| CN-104447285-A | Novel crystal form of calcium levulinate monohydrate | GUANGZHOU BAIYUNSHAN TIANXIN PHARMACEUTICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| EP-4082552-B1 | LIQUIDS RICH IN NOBLE GAS AND METHODS OF THEIR PREPARATION AND USE | UNIV TEXAS (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260014162-A1 | REHYDRATION COMPOSITION AND METHOD OF USE | YourLifeRx, Inc., d/b/a Daywel, Inc. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12383559-B2 | Rehydration composition and method of use | YourLifeRx, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240299397-A1 | REHYDRATION COMPOSITION AND METHOD OF USE | YourLifeRx, Inc., d/b/a Daywel, Inc. (US) | 2024-09-12 | — | — | US | disclosed |
| US-11491184-B2 | Liquids rich in noble gas and methods of their preparation and use | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-08 | — | — | US | disclosed |
| EP-4082552-A1 | LIQUIDS RICH IN NOBLE GAS AND METHODS OF THEIR PREPARATION AND USE | The Board of Regents of the University of Texas System (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-2968126-B1 | LIQUIDS RICH IN NOBLE GAS AND METHODS OF THEIR PREPARATION AND USE | UNIV TEXAS (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-104447285-B | A kind of crystal formation of calcium levulinate monohydrate | 广州白云山天心制药股份有限公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-104447285-B | A kind of crystal formation of calcium levulinate monohydrate | 广州白云山天心制药股份有限公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-104447285-B | A kind of crystal formation of calcium levulinate monohydrate | 广州白云山天心制药股份有限公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-104447285-A | Novel crystal form of calcium levulinate monohydrate | GUANGZHOU BAIYUNSHAN TIANXIN PHARMACEUTICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| CN-104447285-A | Novel crystal form of calcium levulinate monohydrate | GUANGZHOU BAIYUNSHAN TIANXIN PHARMACEUTICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| CN-104447285-A | Novel crystal form of calcium levulinate monohydrate | GUANGZHOU BAIYUNSHAN TIANXIN PHARMACEUTICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8362306-B2 | Energy densification of biomass-derived organic acids | UNIVERSITY OF MAINE SYSTEM BOARD OF TRUSTEES (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2011053584-A1 | ENERGY DENSIFICATION OF BIOMASS-DERIVED ORGANIC ACIDS | UNIVERSITY OF MAINE SYSTEM BOARD OF TRUSTEES (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098503-A1 | ENERGY DENSIFICATION OF BIOMASS-DERIVED ORGANIC ACIDS | UNIVERSITY OF MAINE SYSTEM BOARD OF TRUSTEES | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014162-A1 | REHYDRATION COMPOSITION AND METHOD OF USE | AQP1, SLC5A1, SLC2A1 | HDAC3 548/4885HDAC1 517/4885HDAC2 432/4885 |
| US-20110098503-A1 | ENERGY DENSIFICATION OF BIOMASS-DERIVED ORGANIC ACIDS | ADH1C, ADH1A, ADH5 | HDAC3 2809/4885HDAC1 2340/4885HDAC2 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.